Physician profile
Michael E Abrouk
NPI 1841725330
$33,583.62
in general payments reported to CMS, 2019-2025
23 companies · $28K in 2025
The $28K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,465 · 2020: $540 · 2021: $1,830 · 2022: $341 · 2023: $951 · 2024: $718 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $9,600 · Travel and Lodging: $4,544 · Food and Beverage: $2,873 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,250.00 |
| Consulting Fee | $9,600.00 |
| Travel and Lodging | $4,544.17 |
| Food and Beverage | $2,872.57 |
| Education | $141.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC | $26,962.82 | 2024-2025 | Clear+Brilliant |
| Abbvie INC. | $1,758.94 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $1,342.99 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $613.26 | 2021-2025 | Nemluvio |
| Merz North America, INC. | $401.43 | 2019-2024 | Xeomin |
| Regeneron Healthcare Solutions, INC. | $394.22 | 2019-2023 | Libtayo |
| Allergan, INC. | $378.61 | 2019 | |
| Sun Pharmaceutical Industries INC. | $316.37 | 2022-2023 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $224.30 | 2021-2025 | Tremfya |
| Genzyme Corporation | $185.75 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $170.66 | 2023-2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $149.15 | 2021 | |
| Lilly USA, LLC | $136.31 | 2020-2025 | Ebglyss |
| Ucb, INC. | $123.26 | 2025 | Bimzelx |
| Pfizer INC. | $122.85 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $67.28 | 2021-2024 | |
| Revance Therapeutics, INC. | $60.42 | 2024 | Daxxify |
| Mayne Pharma Commercial LLC | $49.62 | 2025 | |
| Incyte Corporation | $46.71 | 2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.50 | 2023 | Spevigo |
| Journey Medical Corporation | $19.47 | 2025 | |
| Arcutis Biotherapeutics, INC. | $18.78 | 2024 | Zoryve |
| Almirall LLC | $16.92 | 2023 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Abrouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.